Abstract
Discovering new drugs with novel targets is vital for the success of treatment of tuberculosis as antibiotic resistance is increasing among the TB population. Mycobacterium tuberculosis cytochrome P450 CYP121A1 is a promising drug target for the treatment of tuberculosis owing to its essential role in mycobacterium growth. Using a rational approach, that includes molecular docking studies of some substituted pyrazole derivatives a series of pyrazole analogue were designed and pass through computational studies. Compound with good docking score and ADME profile were synthesized using two step reaction and biologically evaluated for their inhibitory activity towards M. tuberculosis. All compounds were analyzed by IR, LCMS, 1H NMR and 13C NMR. Among them 3 compounds shows significant activity having MIC (6.25 µg/ml).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
